-
Company Profile
Enzon Pharmaceuticals Inc – Company Profile
Enzon Pharmaceuticals Inc (Enzon), formerly Enzon Inc, is a biopharmaceutical company together with its subsidiary engages in commercialization and licensing of technologies. It receives royalty revenues from existing licensing arrangements after sales of drug product PegIntron. Enzon's major partners include Sesen, Inc, Servier IP UK Limited, Merck & Co., and others. Enzon is headquartered in Piscataway, New Jersey, the US.
Add to Basket -
Product Insights
Cryptococcosis Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Cryptococcosis Global Clinical Trials Review, H2, 2017" provides an overview of Cryptococcosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptococcosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Lung Transplant Rejection Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Lung Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Lung Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Product Insights
Cryptococcosis Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Cryptococcosis Global Clinical Trials Review, H1, 2016" provides an overview of Cryptococcosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptococcosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Lung Transplant Rejection Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Lung Transplant Rejection Global Clinical Trials Review, H2, 2016" provides an overview of Lung Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Lung Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...